Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Fulacimstat (Primary)
- Indications Kidney disorders; Left ventricular dysfunction; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bayer
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2018 Planned End Date changed from 19 Dec 2018 to 11 Feb 2019.
- 16 Nov 2018 Planned primary completion date changed from 19 Nov 2018 to 10 Dec 2018.